---
title: "Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287761626.md"
description: "On May 27, 2026, Vanda Pharmaceuticals Inc. unveiled that Japan's Ministry of Health, Labour and Welfare (MHLW) had awarded orphan drug designation to imsidolimab, a high-affinity humanized IgG4 monoclonal antibody. Vanda, listed on Nasdaq as VNDA, shared this development."
datetime: "2026-05-27T11:03:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287761626.md)
  - [en](https://longbridge.com/en/news/287761626.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287761626.md)
---

# Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

On May 27, 2026, Vanda Pharmaceuticals Inc. unveiled that Japan's Ministry of Health, Labour and Welfare (MHLW) had awarded orphan drug designation to imsidolimab, a high-affinity humanized IgG4 monoclonal antibody. Vanda, listed on Nasdaq as VNDA, shared this development.

### Related Stocks

- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)

## Related News & Research

- [Vanda shifts into high gear with Schumacher IndyCar sponsorship](https://longbridge.com/en/news/292938888.md)
- [VNDA: Fanapt® sales surged, BYSANTI™ gained FDA approval, and NEREUS™ launched in Q2 2026](https://longbridge.com/en/news/295007537.md)
- [Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP](https://longbridge.com/en/news/295757013.md)
- [Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs](https://longbridge.com/en/news/295007325.md)
- [Artelo Biosciences Q2 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/295796619.md)